The first approved norepinephrine, dopamine, and serotonin reuptake inhibitor for ADHD demonstrated symptom improvements as early as week 1 in phase 3 trials.
Randomized trials suggested exercise may improve visual function while modestly reducing structural markers of myopia, with benefits varying by intervention strategy.
A nationwide birth cohort found lower odds of short sleep at 1 year among infants breastfed during the first 6 months of life, regardless of formula supplementation.
Four-day treatment targeting the prefrontal cortex and cerebellum produced larger reductions in suicidal ideation scores than prefrontal stimulation alone in adolescents with major depressive disorder.
From Medicare payment updates to drug approvals and device access, these federal actions may affect reimbursement, prescribing, patient access, and clinical workflows.